solriamfetol

General information

• Class: Adjunctive therapy
• Common US brands: Sunosi
• Typical dose range: Administer once daily upon awakening; avoid dosing within 9 hours of planned bedtime (label).
• Therapeutic drug monitoring not routinely recommended.
• Last reviewed: 2026-02-12

Dosing & forms

• Forms/strengths: Tablets: 75 mg (functionally scored) and 150 mg (label).
• Frequency: Administer once daily upon awakening; avoid dosing within 9 hours of planned bedtime (label).
• Typical range: Administer once daily upon awakening; avoid dosing within 9 hours of planned bedtime (label).

Mechanism (brief)

Wakefulness-promoting dopamine and norepinephrine reuptake inhibitor (solriamfetol) indicated to improve wakefulness in adults with excessive sleepiness associated with narcolepsy or obstructive sleep apnea; Schedule IV with dose-dependent blood pressure/heart rate effects and MAOI contraindication.

Metabolism & Half‑life

• Metabolism: Minimal metabolism (minor inactive N-acetyl metabolite)
• Half‑life: Single-dose mean 7.1 h

Therapeutic Drug Monitoring (TDM)

Recommended: No

Monitoring highlights

• Blood pressure and heart rate monitoring at baseline and periodically (label/clinical).
• Sleep disruption monitoring (insomnia, timing effects) (label/clinical).
• Mood and psychiatric symptom monitoring (anxiety, irritability, mania/psychosis) (label/clinical).
• Renal function review for dosing decisions and ongoing safety (label).
• Misuse/diversion risk monitoring consistent with Schedule IV status (clinical).

Sources

• SUNOSI (solriamfetol) tablets prescribing information — DailyMed (2026)
• Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline — Journal of Clinical Sleep Medicine (2021)
• Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment — Journal of Clinical Sleep Medicine (2021)
• A randomized study of solriamfetol for excessive sleepiness in narcolepsy — Annals of Neurology (2019)
• Solriamfetol for Excessive Sleepiness in Obstructive Sleep Apnea (TONES 3). A Randomized Controlled Trial — American Journal of Respiratory and Critical Care Medicine (2019)